Format

Send to

Choose Destination
Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):329-337. doi: 10.1080/17474124.2017.1292851. Epub 2017 Feb 16.

Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

Author information

1
a Institute of Experimental and Clinical Pharmacology , Medical University of Graz , Graz , Austria.
2
b Department of Medicine , Ludwig-Maximilians University , Munich , Germany.
3
c Zentrum für Endoskopie , Starnberg , Germany.

Abstract

Fifty years after the discovery of Δ9-tetrahydrocannabinol (THC) as the psychoactive component of Cannabis, we are assessing the possibility of translating this herb into clinical treatment of inflammatory bowel diseases (IBDs). Here, a discussion on the problems associated with a potential treatment is given. From first surveys and small clinical studies in patients with IBD we have learned that Cannabis is frequently used to alleviate diarrhea, abdominal pain, and loss of appetite. Single ingredients from Cannabis, such as THC and cannabidiol, commonly described as cannabinoids, are responsible for these effects. Synthetic cannabinoid receptor agonists are also termed cannabinoids, some of which, like dronabinol and nabilone, are already available with a narcotic prescription. Areas covered: Recent data on the effects of Cannabis/cannabinoids in experimental models of IBD and in clinical trials with IBD patients have been reviewed using a PubMed database search. A short background on the endocannabinoid system is also provided. Expert commentary: Cannabinoids could be helpful for certain symptoms of IBD, but there is still a lack of clinical studies to prove efficacy, tolerability and safety of cannabinoid-based medication for IBD patients, leaving medical professionals without evidence and guidelines.

KEYWORDS:

Cannabinoids; Cannabis; Crohn’s disease; dronabinol; inflammatory bowel disease; medical marijuana; nabilone; nabiximols; ulcerative colitis

PMID:
28276820
PMCID:
PMC5388177
DOI:
10.1080/17474124.2017.1292851
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center